🍀 Happy St. Patrick's Day! NEW: Brave Butterfly - Bonds of Boston. How I paralleled my journey with Tatum's comeback. Adversity doesn't end the game—it teaches us how to begin.
Stay informed about the latest hypoparathyroidism research, clinical trials, and advocacy updates
Bari Gordon Vapnek shares her inspiring story as Patient #1 in the TransCon PTH clinical trial at two major conferences, advocating for hypoparathyroidism awareness and patient voices in medical research.
MBX Biosciences announced successful completion of End-of-Phase 2 meeting with FDA and outlined Phase 3 development plan for Canvuparatide, a once-weekly treatment for hypoparathyroidism.
Bari Gordon Vapnek celebrates International Women's Day with the inspiring Eleanor Roosevelt quote: 'A woman is like a tea bag; you never know how strong it is until it's in hot water.'
Brave Butterfly Bari launches comprehensive Health & Wellness Hub featuring the 'Get Moving with Bari' Spotify playlist and integrated wellness resources.
Brave Butterfly Bari announces new donation system with automatic email notifications, making it easier for supporters to contribute and receive updates.
New Analytics Dashboard provides real-time insights into community engagement, page views, and content performance metrics.
Brave Butterfly Bari launches internal search functionality allowing visitors to easily find content across 45+ pages of resources, stories, and information.
Entera Bio presented clinical data on EB612, the first oral formulation of PTH (1-34) hormone replacement treatment for hypoparathyroidism, at the 2024 ENDO Conference.
Bari Gordon Vapnek shares her inspiring story as Patient #1 in the TransCon PTH clinical trial at two major conferences, advocating for hypoparathyroidism awareness and patient voices in medical research.
Subscribe to receive breaking news, clinical trial updates, and FDA announcements about hypoparathyroidism treatment advances.
We respect your privacy. Unsubscribe at any time.